[ad_1]
This article is over a month old and may contain outdated advice from authorities regarding coronary heart disease.
Stay up to date on the NRK overview or on the FHI website.
The UK, Bahrain and Canada have already approved the vaccine for BioNTech / Pfizer. The United States can now become the fourth country. The AP calls it a big step in the direction of mass vaccination against the coronavirus.
– Safe to take
Experts say the vaccine works effectively and is safe for those over 16 years of age.
Several countries around the world have placed large orders. The first 30,000 doses of the vaccine are expected to arrive in Canada in the next few days, after the country approved the vaccine on Wednesday this week. The vaccine will be ready for use on Monday, health authorities told Reuters.
Pfizer requested urgent approval for use in the United States on November 20. So far, it has a group of experts in the Food and Drug Administration (FDA), which approves vaccines in the United States. worked on reviewing data material from vaccine studies.
Only four voted against
The FDA is an agency of the US Department of Health and Social Affairs and can be compared to the Norwegian Agency for Medicines. On Thursday, FDA experts and Pfizer representatives discussed the vaccine data in a meeting lasting more than eight hours. The panel is made up of specialists in vaccine development, infectious diseases and medical statistics.
The result was that the expert committee (VRBPAC) recommended its approval. Only four of the 22 members of the expert group voted against the approval.
The FDA is expected to follow the advice of the expert group, although they are not required to do so.
The approval of the vaccine comes at a time when the world is hit by new waves of coronary heart disease. So far, the virus has claimed more than 1.5 million lives, 290,000 of them in the United States alone.
Known as “a triumph”
According to Pfizer, the company will be able to offer the United States 25 million doses of the vaccine, to be taken in two doses, before the new year.
However, the supply of vaccines will be limited initially and doses will be offered mainly to health personnel and residents of nursing homes. Next in line are others in risk groups, until the vaccine is widely available, probably not until spring.
The results of the Pfizer and Biontech vaccines were published this week and peer-reviewed in the New England Journal of Medicine. The test results are called a “win.”
The results of the AstraZeneca and Oxford University vaccines were published in The Lancet on Tuesday.
